This inventor holds 2 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: La Trobe University, Transbio Ltd. Active years: 2015-2019.
Company Filing History:
Years Active: 2015-2019
Title: John Silke: Innovator in Fn14 Binding Proteins
Introduction
John Silke is a notable inventor based in Melbourne, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of proteins that target Fn14. With a total of 2 patents, his work has implications for treating various wasting disorders, including cachexia.
Latest Patents
Silke's latest patents focus on Fn14 binding proteins and their uses. The present disclosure provides proteins comprising antibody antigen binding domains that bind to Fn14 and outlines methods for treating wasting disorders. This innovative approach has the potential to improve the quality of life for individuals suffering from these conditions.
Career Highlights
Throughout his career, John Silke has worked with esteemed institutions such as La Trobe University and Transbio Ltd. His experience in these organizations has allowed him to collaborate with other experts in the field and further his research in biotechnology.
Collaborations
Some of his notable coworkers include Amelia Jane Johnston and Nicholas Johannes Hoogenraad. Their collaborative efforts have contributed to the advancement of research in the area of Fn14 binding proteins.
Conclusion
John Silke's contributions to biotechnology, particularly through his patents on Fn14 binding proteins, highlight his role as an innovator in the field. His work continues to pave the way for new treatments for wasting disorders, showcasing the importance of research and collaboration in scientific advancements.